Yahoo · Sep 24, 2026
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
GK
NYSE · GKOS
Glaukos Corporation
Healthcare · Medical - Devices
$161.59
Down-$2.42 (-1.48%)
Updated Oct 7, 2026, 10:36 AM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 6.27B
- P/E ratio
- -71.17
- Dividend yield
- 0.00%
- 52-week range
- $95.87 – $191.62
- Volume
- 664.41K
- Avg. volume
- 1.14M
Price performance · GKOS
GKOS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
GKOS closed at $161.59 after 21 trading sessions, down 12.67% for the selected period.
- Last close
- $161.59
- Period change
- -12.67%
- Period low
- $153.49
- Period high
- $185.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $163.84 | $164.00 | $160.30 | $161.59 | 664.41K |
| Oct 5, 2026 | $164.44 | $165.99 | $163.17 | $164.01 | 837.81K |
| Oct 2, 2026 | $167.57 | $168.08 | $163.01 | $163.75 | 742.81K |
| Oct 1, 2026 | $164.00 | $168.73 | $162.08 | $163.17 | 808.41K |
| Sep 30, 2026 | $158.31 | $165.645 | $157.29 | $164.19 | 947.09K |
| Sep 29, 2026 | $153.56 | $159.06 | $152.39 | $158.55 | 638.2K |
| Sep 28, 2026 | $153.11 | $160.98 | $151.71 | $158.56 | 1.4M |
| Sep 25, 2026 | $154.50 | $155.595 | $151.01 | $154.43 | 826.24K |
| Sep 24, 2026 | $153.70 | $156.65 | $152.75 | $154.88 | 838.4K |
| Sep 23, 2026 | $159.86 | $162.04 | $153.31 | $153.49 | 1.03M |
| Sep 22, 2026 | $165.36 | $165.36 | $159.00 | $159.86 | 1.1M |
| Sep 21, 2026 | $166.27 | $166.7354 | $160.23 | $161.53 | 806.47K |
| Sep 18, 2026 | $160.60 | $163.85 | $159.01 | $163.81 | 1.46M |
| Sep 17, 2026 | $164.13 | $166.355 | $160.68 | $161.42 | 646.8K |
| Sep 16, 2026 | $172.01 | $173.545 | $162.12 | $163.47 | 690.99K |
| Sep 15, 2026 | $169.75 | $172.76 | $167.97 | $171.68 | 621.75K |
| Sep 14, 2026 | $168.51 | $171.36 | $165.43 | $171.09 | 906.31K |
| Sep 11, 2026 | $174.12 | $175.375 | $166.74 | $167.25 | 552.41K |
| Sep 10, 2026 | $176.50 | $179.96 | $169.26 | $170.38 | 1.01M |
| Sep 9, 2026 | $183.15 | $183.33 | $178.52 | $179.79 | 587.94K |
| Sep 8, 2026 | $175.55 | $185.35 | $172.98 | $185.04 | 1.16M |
Latest GKOS news
The latest Smart Investors Daily articles mentioning GKOS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GKOS research
Overview
Company profile and research snapshot.
Company profile
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $121.38
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | Jefferies | Buy | — |
| Aug 20, 2026 | BTIG | Buy | — |
| Jul 30, 2026 | Needham | Buy | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| Jul 30, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 23, 2026
$1000 Invested In Glaukos 10 Years Ago Would Be Worth This Much Today
Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 1.4% on an annualized basis producing an average annual return of 14.97%. Currently, Glaukos has a market capitalization of $9.57 billion.
Yahoo · Sep 23, 2026
Glaukos Partners with NBA Champion Stephen Curry to Launch "Could it be KC?" Campaign to Raise Awareness of Keratoconus
ALISO VIEJO, Calif., September 23, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational campaign launching today with expanding activities planned in 2027 aimed at improving recognition and earlier detection of keratoconus (KC), a rare, progressive, sight-threatening
Yahoo · Sep 23, 2026
Glaukos (GKOS) Stock Looks Fully Priced Against Its Sales Growth Story
Glaukos has delivered very strong long term share gains, which puts a spotlight on whether the current US$159.86 price still lines up with what the company is generating in sales. After a run like this, the question is how much of that performance is already reflected in the revenue multiple investors are paying today. Over the past 5 years the stock has gained 219.9%, which puts a lot of weight on whether the sales base can support that kind of re-rating. The business model is heavily tied...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
